Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Gefitinib

ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)

DRUG

Anastrozole

1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO

Trial Locations (27)

Unknown

Research Site, La Jolla

Research Site, San Diego

Research Site, Orlando

Research Site, Lafayette

Research Site, Rockville

Research Site, Columbia

Research Site, Omaha

Research Site, Las Vegas

Research Site, Voorhees Township

Research Site, Albuquerque

Research Site, Lake Success

Research Site, Cincinnati

Research Site, Allentown

Research Site, Sioux Falls

Research Site, Houston

Research Site, Temple

Research Site, Santiago de Cali

Research Site, Aguascalientes

Research Site, Guadalajara

Research Site, Morelia

Research Site, Barcelona

Research Site, Barquisimeto

Research Site, Caracas

Research Site, Maracaibo

Research Site, Puerto Ordaz and San Felix

Research Site, San Cristóbal

Research Site, Valencia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY